nodes	percent_of_prediction	percent_of_DWPC	metapath
Epoprostenol—PTGER1—breast cancer	0.569	1	CbGaD
Epoprostenol—CYP2C9—Anastrozole—breast cancer	0.0363	0.332	CbGbCtD
Epoprostenol—CYP2C9—Idarubicin—breast cancer	0.0275	0.252	CbGbCtD
Epoprostenol—CYP2C9—Capecitabine—breast cancer	0.0151	0.138	CbGbCtD
Epoprostenol—CYP2C9—Tamoxifen—breast cancer	0.0121	0.111	CbGbCtD
Epoprostenol—CYP2C9—Paclitaxel—breast cancer	0.00944	0.0863	CbGbCtD
Epoprostenol—CYP2C9—Fluorouracil—breast cancer	0.00894	0.0817	CbGbCtD
Epoprostenol—P2RY12—epithelium—breast cancer	0.00218	0.0767	CbGeAlD
Epoprostenol—PTGIS—uterus—breast cancer	0.002	0.0704	CbGeAlD
Epoprostenol—PTGIS—adipose tissue—breast cancer	0.00196	0.0688	CbGeAlD
Epoprostenol—PTGIS—female reproductive system—breast cancer	0.0018	0.0633	CbGeAlD
Epoprostenol—PTGIS—adrenal gland—breast cancer	0.00175	0.0617	CbGeAlD
Epoprostenol—PTGER1—female reproductive system—breast cancer	0.00167	0.0588	CbGeAlD
Epoprostenol—PTGIS—female gonad—breast cancer	0.00164	0.0576	CbGeAlD
Epoprostenol—PTGIS—endocrine gland—breast cancer	0.00152	0.0535	CbGeAlD
Epoprostenol—PTGER1—female gonad—breast cancer	0.00152	0.0535	CbGeAlD
Epoprostenol—PTGER1—endocrine gland—breast cancer	0.00141	0.0498	CbGeAlD
Epoprostenol—PTGIR—epithelium—breast cancer	0.00139	0.0489	CbGeAlD
Epoprostenol—P2RY12—endocrine gland—breast cancer	0.00137	0.0482	CbGeAlD
Epoprostenol—Bimatoprost—PTGER1—breast cancer	0.00134	0.259	CrCbGaD
Epoprostenol—PTGIR—adipose tissue—breast cancer	0.00112	0.0395	CbGeAlD
Epoprostenol—PTGIS—lymph node—breast cancer	0.00105	0.037	CbGeAlD
Epoprostenol—PTGIR—female reproductive system—breast cancer	0.00103	0.0363	CbGeAlD
Epoprostenol—Alprostadil—PTGER1—breast cancer	0.00101	0.196	CrCbGaD
Epoprostenol—PTGIR—adrenal gland—breast cancer	0.00101	0.0355	CbGeAlD
Epoprostenol—PTGIR—female gonad—breast cancer	0.000939	0.0331	CbGeAlD
Epoprostenol—CYP2C9—mammary gland—breast cancer	0.000892	0.0314	CbGeAlD
Epoprostenol—PTGIR—endocrine gland—breast cancer	0.000874	0.0307	CbGeAlD
Epoprostenol—Dinoprost Tromethamine—PTGER1—breast cancer	0.000809	0.157	CrCbGaD
Epoprostenol—Dinoprostone—PTGER1—breast cancer	0.000622	0.12	CrCbGaD
Epoprostenol—PTGIR—lymph node—breast cancer	0.000604	0.0213	CbGeAlD
Epoprostenol—Dinoprost Tromethamine—HPGDS—breast cancer	0.00055	0.106	CrCbGaD
Epoprostenol—Dinoprostone—HPGDS—breast cancer	0.000423	0.0819	CrCbGaD
Epoprostenol—CYP2C9—female reproductive system—breast cancer	0.000369	0.013	CbGeAlD
Epoprostenol—CYP2C9—endocrine gland—breast cancer	0.000312	0.011	CbGeAlD
Epoprostenol—Dinoprostone—SLCO1B1—breast cancer	0.000284	0.0549	CrCbGaD
Epoprostenol—Dinoprostone—CYP19A1—breast cancer	0.000131	0.0254	CrCbGaD
Epoprostenol—Sinusitis—Doxorubicin—breast cancer	3.9e-05	0.000223	CcSEcCtD
Epoprostenol—Dizziness—Fluorouracil—breast cancer	3.89e-05	0.000222	CcSEcCtD
Epoprostenol—Mediastinal disorder—Methotrexate—breast cancer	3.88e-05	0.000222	CcSEcCtD
Epoprostenol—Rash—Mitoxantrone—breast cancer	3.87e-05	0.000221	CcSEcCtD
Epoprostenol—Rash—Irinotecan—breast cancer	3.87e-05	0.000221	CcSEcCtD
Epoprostenol—Dermatitis—Mitoxantrone—breast cancer	3.87e-05	0.000221	CcSEcCtD
Epoprostenol—Dermatitis—Irinotecan—breast cancer	3.87e-05	0.000221	CcSEcCtD
Epoprostenol—Musculoskeletal discomfort—Docetaxel—breast cancer	3.87e-05	0.000221	CcSEcCtD
Epoprostenol—Chills—Methotrexate—breast cancer	3.87e-05	0.000221	CcSEcCtD
Epoprostenol—Headache—Irinotecan—breast cancer	3.85e-05	0.00022	CcSEcCtD
Epoprostenol—Headache—Mitoxantrone—breast cancer	3.85e-05	0.00022	CcSEcCtD
Epoprostenol—Hypotension—Capecitabine—breast cancer	3.84e-05	0.000219	CcSEcCtD
Epoprostenol—Insomnia—Docetaxel—breast cancer	3.84e-05	0.000219	CcSEcCtD
Epoprostenol—Paraesthesia—Docetaxel—breast cancer	3.81e-05	0.000218	CcSEcCtD
Epoprostenol—Vomiting—Gemcitabine—breast cancer	3.81e-05	0.000217	CcSEcCtD
Epoprostenol—Bradycardia—Doxorubicin—breast cancer	3.8e-05	0.000217	CcSEcCtD
Epoprostenol—Dyspnoea—Docetaxel—breast cancer	3.79e-05	0.000216	CcSEcCtD
Epoprostenol—Somnolence—Docetaxel—breast cancer	3.78e-05	0.000216	CcSEcCtD
Epoprostenol—Mental disorder—Methotrexate—breast cancer	3.78e-05	0.000215	CcSEcCtD
Epoprostenol—Rash—Gemcitabine—breast cancer	3.77e-05	0.000215	CcSEcCtD
Epoprostenol—Dermatitis—Gemcitabine—breast cancer	3.77e-05	0.000215	CcSEcCtD
Epoprostenol—Haemoglobin—Doxorubicin—breast cancer	3.75e-05	0.000214	CcSEcCtD
Epoprostenol—Headache—Gemcitabine—breast cancer	3.75e-05	0.000214	CcSEcCtD
Epoprostenol—Musculoskeletal discomfort—Capecitabine—breast cancer	3.75e-05	0.000214	CcSEcCtD
Epoprostenol—Flushing—Epirubicin—breast cancer	3.74e-05	0.000214	CcSEcCtD
Epoprostenol—Cardiac disorder—Epirubicin—breast cancer	3.74e-05	0.000214	CcSEcCtD
Epoprostenol—Vomiting—Fluorouracil—breast cancer	3.74e-05	0.000214	CcSEcCtD
Epoprostenol—Rhinitis—Doxorubicin—breast cancer	3.74e-05	0.000214	CcSEcCtD
Epoprostenol—Dyspepsia—Docetaxel—breast cancer	3.74e-05	0.000213	CcSEcCtD
Epoprostenol—Haemorrhage—Doxorubicin—breast cancer	3.73e-05	0.000213	CcSEcCtD
Epoprostenol—Insomnia—Capecitabine—breast cancer	3.72e-05	0.000212	CcSEcCtD
Epoprostenol—Hypoaesthesia—Doxorubicin—breast cancer	3.71e-05	0.000212	CcSEcCtD
Epoprostenol—Rash—Fluorouracil—breast cancer	3.71e-05	0.000212	CcSEcCtD
Epoprostenol—Dermatitis—Fluorouracil—breast cancer	3.71e-05	0.000212	CcSEcCtD
Epoprostenol—Pharyngitis—Doxorubicin—breast cancer	3.7e-05	0.000211	CcSEcCtD
Epoprostenol—Paraesthesia—Capecitabine—breast cancer	3.69e-05	0.000211	CcSEcCtD
Epoprostenol—Decreased appetite—Docetaxel—breast cancer	3.69e-05	0.000211	CcSEcCtD
Epoprostenol—Hypersensitivity—Paclitaxel—breast cancer	3.69e-05	0.000211	CcSEcCtD
Epoprostenol—Headache—Fluorouracil—breast cancer	3.69e-05	0.00021	CcSEcCtD
Epoprostenol—Oedema peripheral—Doxorubicin—breast cancer	3.68e-05	0.00021	CcSEcCtD
Epoprostenol—Gastrointestinal disorder—Docetaxel—breast cancer	3.67e-05	0.000209	CcSEcCtD
Epoprostenol—Connective tissue disorder—Doxorubicin—breast cancer	3.67e-05	0.000209	CcSEcCtD
Epoprostenol—Dyspnoea—Capecitabine—breast cancer	3.67e-05	0.000209	CcSEcCtD
Epoprostenol—Fatigue—Docetaxel—breast cancer	3.66e-05	0.000209	CcSEcCtD
Epoprostenol—Angiopathy—Epirubicin—breast cancer	3.66e-05	0.000209	CcSEcCtD
Epoprostenol—Nausea—Mitoxantrone—breast cancer	3.65e-05	0.000208	CcSEcCtD
Epoprostenol—Nausea—Irinotecan—breast cancer	3.65e-05	0.000208	CcSEcCtD
Epoprostenol—Mediastinal disorder—Epirubicin—breast cancer	3.63e-05	0.000207	CcSEcCtD
Epoprostenol—Pain—Docetaxel—breast cancer	3.63e-05	0.000207	CcSEcCtD
Epoprostenol—Constipation—Docetaxel—breast cancer	3.63e-05	0.000207	CcSEcCtD
Epoprostenol—Back pain—Methotrexate—breast cancer	3.63e-05	0.000207	CcSEcCtD
Epoprostenol—Dyspepsia—Capecitabine—breast cancer	3.62e-05	0.000207	CcSEcCtD
Epoprostenol—Chills—Epirubicin—breast cancer	3.62e-05	0.000207	CcSEcCtD
Epoprostenol—Asthenia—Paclitaxel—breast cancer	3.6e-05	0.000205	CcSEcCtD
Epoprostenol—Decreased appetite—Capecitabine—breast cancer	3.58e-05	0.000204	CcSEcCtD
Epoprostenol—Nausea—Gemcitabine—breast cancer	3.56e-05	0.000203	CcSEcCtD
Epoprostenol—Gastrointestinal disorder—Capecitabine—breast cancer	3.55e-05	0.000203	CcSEcCtD
Epoprostenol—Fatigue—Capecitabine—breast cancer	3.55e-05	0.000202	CcSEcCtD
Epoprostenol—Pruritus—Paclitaxel—breast cancer	3.55e-05	0.000202	CcSEcCtD
Epoprostenol—Mental disorder—Epirubicin—breast cancer	3.53e-05	0.000202	CcSEcCtD
Epoprostenol—Pain—Capecitabine—breast cancer	3.52e-05	0.000201	CcSEcCtD
Epoprostenol—Constipation—Capecitabine—breast cancer	3.52e-05	0.000201	CcSEcCtD
Epoprostenol—Nausea—Fluorouracil—breast cancer	3.5e-05	0.0002	CcSEcCtD
Epoprostenol—Gastrointestinal pain—Docetaxel—breast cancer	3.47e-05	0.000198	CcSEcCtD
Epoprostenol—Anaemia—Methotrexate—breast cancer	3.47e-05	0.000198	CcSEcCtD
Epoprostenol—Flushing—Doxorubicin—breast cancer	3.46e-05	0.000198	CcSEcCtD
Epoprostenol—Cardiac disorder—Doxorubicin—breast cancer	3.46e-05	0.000198	CcSEcCtD
Epoprostenol—Flatulence—Epirubicin—breast cancer	3.46e-05	0.000197	CcSEcCtD
Epoprostenol—Tension—Epirubicin—breast cancer	3.45e-05	0.000197	CcSEcCtD
Epoprostenol—Diarrhoea—Paclitaxel—breast cancer	3.43e-05	0.000196	CcSEcCtD
Epoprostenol—Nervousness—Epirubicin—breast cancer	3.41e-05	0.000195	CcSEcCtD
Epoprostenol—Back pain—Epirubicin—breast cancer	3.4e-05	0.000194	CcSEcCtD
Epoprostenol—Angiopathy—Doxorubicin—breast cancer	3.39e-05	0.000193	CcSEcCtD
Epoprostenol—Muscle spasms—Epirubicin—breast cancer	3.38e-05	0.000193	CcSEcCtD
Epoprostenol—Gastrointestinal pain—Capecitabine—breast cancer	3.36e-05	0.000192	CcSEcCtD
Epoprostenol—Mediastinal disorder—Doxorubicin—breast cancer	3.36e-05	0.000192	CcSEcCtD
Epoprostenol—Body temperature increased—Docetaxel—breast cancer	3.36e-05	0.000192	CcSEcCtD
Epoprostenol—Abdominal pain—Docetaxel—breast cancer	3.36e-05	0.000192	CcSEcCtD
Epoprostenol—Chills—Doxorubicin—breast cancer	3.35e-05	0.000191	CcSEcCtD
Epoprostenol—Dizziness—Paclitaxel—breast cancer	3.31e-05	0.000189	CcSEcCtD
Epoprostenol—Cough—Methotrexate—breast cancer	3.27e-05	0.000187	CcSEcCtD
Epoprostenol—Mental disorder—Doxorubicin—breast cancer	3.27e-05	0.000187	CcSEcCtD
Epoprostenol—Urticaria—Capecitabine—breast cancer	3.27e-05	0.000186	CcSEcCtD
Epoprostenol—Abdominal pain—Capecitabine—breast cancer	3.25e-05	0.000186	CcSEcCtD
Epoprostenol—Body temperature increased—Capecitabine—breast cancer	3.25e-05	0.000186	CcSEcCtD
Epoprostenol—Anaemia—Epirubicin—breast cancer	3.24e-05	0.000185	CcSEcCtD
Epoprostenol—Agitation—Epirubicin—breast cancer	3.23e-05	0.000184	CcSEcCtD
Epoprostenol—Flatulence—Doxorubicin—breast cancer	3.2e-05	0.000183	CcSEcCtD
Epoprostenol—Chest pain—Methotrexate—breast cancer	3.19e-05	0.000182	CcSEcCtD
Epoprostenol—Arthralgia—Methotrexate—breast cancer	3.19e-05	0.000182	CcSEcCtD
Epoprostenol—Myalgia—Methotrexate—breast cancer	3.19e-05	0.000182	CcSEcCtD
Epoprostenol—Tension—Doxorubicin—breast cancer	3.19e-05	0.000182	CcSEcCtD
Epoprostenol—Vomiting—Paclitaxel—breast cancer	3.19e-05	0.000182	CcSEcCtD
Epoprostenol—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—breast cancer	3.17e-05	0.000181	CcSEcCtD
Epoprostenol—Rash—Paclitaxel—breast cancer	3.16e-05	0.00018	CcSEcCtD
Epoprostenol—Dermatitis—Paclitaxel—breast cancer	3.16e-05	0.00018	CcSEcCtD
Epoprostenol—Nervousness—Doxorubicin—breast cancer	3.15e-05	0.00018	CcSEcCtD
Epoprostenol—Syncope—Epirubicin—breast cancer	3.15e-05	0.00018	CcSEcCtD
Epoprostenol—Back pain—Doxorubicin—breast cancer	3.14e-05	0.000179	CcSEcCtD
Epoprostenol—Headache—Paclitaxel—breast cancer	3.14e-05	0.000179	CcSEcCtD
Epoprostenol—Hypersensitivity—Docetaxel—breast cancer	3.13e-05	0.000179	CcSEcCtD
Epoprostenol—Muscle spasms—Doxorubicin—breast cancer	3.12e-05	0.000178	CcSEcCtD
Epoprostenol—Palpitations—Epirubicin—breast cancer	3.1e-05	0.000177	CcSEcCtD
Epoprostenol—Confusional state—Methotrexate—breast cancer	3.09e-05	0.000176	CcSEcCtD
Epoprostenol—Loss of consciousness—Epirubicin—breast cancer	3.09e-05	0.000176	CcSEcCtD
Epoprostenol—Cough—Epirubicin—breast cancer	3.06e-05	0.000175	CcSEcCtD
Epoprostenol—Anaphylactic shock—Methotrexate—breast cancer	3.06e-05	0.000175	CcSEcCtD
Epoprostenol—Asthenia—Docetaxel—breast cancer	3.05e-05	0.000174	CcSEcCtD
Epoprostenol—Infection—Methotrexate—breast cancer	3.04e-05	0.000174	CcSEcCtD
Epoprostenol—Hypersensitivity—Capecitabine—breast cancer	3.03e-05	0.000173	CcSEcCtD
Epoprostenol—Pruritus—Docetaxel—breast cancer	3.01e-05	0.000172	CcSEcCtD
Epoprostenol—Nervous system disorder—Methotrexate—breast cancer	3e-05	0.000171	CcSEcCtD
Epoprostenol—Anaemia—Doxorubicin—breast cancer	3e-05	0.000171	CcSEcCtD
Epoprostenol—Thrombocytopenia—Methotrexate—breast cancer	3e-05	0.000171	CcSEcCtD
Epoprostenol—Chest pain—Epirubicin—breast cancer	2.99e-05	0.000171	CcSEcCtD
Epoprostenol—Myalgia—Epirubicin—breast cancer	2.99e-05	0.000171	CcSEcCtD
Epoprostenol—Arthralgia—Epirubicin—breast cancer	2.99e-05	0.000171	CcSEcCtD
Epoprostenol—Agitation—Doxorubicin—breast cancer	2.99e-05	0.00017	CcSEcCtD
Epoprostenol—Anxiety—Epirubicin—breast cancer	2.98e-05	0.00017	CcSEcCtD
Epoprostenol—Nausea—Paclitaxel—breast cancer	2.98e-05	0.00017	CcSEcCtD
Epoprostenol—Skin disorder—Methotrexate—breast cancer	2.97e-05	0.00017	CcSEcCtD
Epoprostenol—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—breast cancer	2.97e-05	0.000169	CcSEcCtD
Epoprostenol—Hyperhidrosis—Methotrexate—breast cancer	2.96e-05	0.000169	CcSEcCtD
Epoprostenol—Asthenia—Capecitabine—breast cancer	2.95e-05	0.000168	CcSEcCtD
Epoprostenol—Dry mouth—Epirubicin—breast cancer	2.92e-05	0.000167	CcSEcCtD
Epoprostenol—Anorexia—Methotrexate—breast cancer	2.92e-05	0.000167	CcSEcCtD
Epoprostenol—Syncope—Doxorubicin—breast cancer	2.91e-05	0.000166	CcSEcCtD
Epoprostenol—Pruritus—Capecitabine—breast cancer	2.91e-05	0.000166	CcSEcCtD
Epoprostenol—Diarrhoea—Docetaxel—breast cancer	2.91e-05	0.000166	CcSEcCtD
Epoprostenol—Confusional state—Epirubicin—breast cancer	2.89e-05	0.000165	CcSEcCtD
Epoprostenol—Palpitations—Doxorubicin—breast cancer	2.87e-05	0.000164	CcSEcCtD
Epoprostenol—Anaphylactic shock—Epirubicin—breast cancer	2.87e-05	0.000164	CcSEcCtD
Epoprostenol—Oedema—Epirubicin—breast cancer	2.87e-05	0.000164	CcSEcCtD
Epoprostenol—Hypotension—Methotrexate—breast cancer	2.86e-05	0.000163	CcSEcCtD
Epoprostenol—Loss of consciousness—Doxorubicin—breast cancer	2.86e-05	0.000163	CcSEcCtD
Epoprostenol—Infection—Epirubicin—breast cancer	2.85e-05	0.000162	CcSEcCtD
Epoprostenol—Cough—Doxorubicin—breast cancer	2.83e-05	0.000162	CcSEcCtD
Epoprostenol—Shock—Epirubicin—breast cancer	2.82e-05	0.000161	CcSEcCtD
Epoprostenol—Diarrhoea—Capecitabine—breast cancer	2.81e-05	0.000161	CcSEcCtD
Epoprostenol—Nervous system disorder—Epirubicin—breast cancer	2.81e-05	0.00016	CcSEcCtD
Epoprostenol—Dizziness—Docetaxel—breast cancer	2.81e-05	0.00016	CcSEcCtD
Epoprostenol—Thrombocytopenia—Epirubicin—breast cancer	2.81e-05	0.00016	CcSEcCtD
Epoprostenol—Tachycardia—Epirubicin—breast cancer	2.8e-05	0.00016	CcSEcCtD
Epoprostenol—Musculoskeletal discomfort—Methotrexate—breast cancer	2.79e-05	0.000159	CcSEcCtD
Epoprostenol—Skin disorder—Epirubicin—breast cancer	2.78e-05	0.000159	CcSEcCtD
Epoprostenol—Hyperhidrosis—Epirubicin—breast cancer	2.77e-05	0.000158	CcSEcCtD
Epoprostenol—Insomnia—Methotrexate—breast cancer	2.77e-05	0.000158	CcSEcCtD
Epoprostenol—Chest pain—Doxorubicin—breast cancer	2.77e-05	0.000158	CcSEcCtD
Epoprostenol—Arthralgia—Doxorubicin—breast cancer	2.77e-05	0.000158	CcSEcCtD
Epoprostenol—Myalgia—Doxorubicin—breast cancer	2.77e-05	0.000158	CcSEcCtD
Epoprostenol—Anxiety—Doxorubicin—breast cancer	2.76e-05	0.000157	CcSEcCtD
Epoprostenol—Paraesthesia—Methotrexate—breast cancer	2.75e-05	0.000157	CcSEcCtD
Epoprostenol—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—breast cancer	2.75e-05	0.000157	CcSEcCtD
Epoprostenol—Anorexia—Epirubicin—breast cancer	2.73e-05	0.000156	CcSEcCtD
Epoprostenol—Dyspnoea—Methotrexate—breast cancer	2.73e-05	0.000156	CcSEcCtD
Epoprostenol—Somnolence—Methotrexate—breast cancer	2.72e-05	0.000155	CcSEcCtD
Epoprostenol—Dizziness—Capecitabine—breast cancer	2.72e-05	0.000155	CcSEcCtD
Epoprostenol—Dry mouth—Doxorubicin—breast cancer	2.7e-05	0.000154	CcSEcCtD
Epoprostenol—Vomiting—Docetaxel—breast cancer	2.7e-05	0.000154	CcSEcCtD
Epoprostenol—Dyspepsia—Methotrexate—breast cancer	2.7e-05	0.000154	CcSEcCtD
Epoprostenol—Rash—Docetaxel—breast cancer	2.68e-05	0.000153	CcSEcCtD
Epoprostenol—Hypotension—Epirubicin—breast cancer	2.68e-05	0.000153	CcSEcCtD
Epoprostenol—Dermatitis—Docetaxel—breast cancer	2.68e-05	0.000153	CcSEcCtD
Epoprostenol—Confusional state—Doxorubicin—breast cancer	2.67e-05	0.000153	CcSEcCtD
Epoprostenol—Decreased appetite—Methotrexate—breast cancer	2.66e-05	0.000152	CcSEcCtD
Epoprostenol—Headache—Docetaxel—breast cancer	2.66e-05	0.000152	CcSEcCtD
Epoprostenol—Anaphylactic shock—Doxorubicin—breast cancer	2.65e-05	0.000151	CcSEcCtD
Epoprostenol—Oedema—Doxorubicin—breast cancer	2.65e-05	0.000151	CcSEcCtD
Epoprostenol—Gastrointestinal disorder—Methotrexate—breast cancer	2.64e-05	0.000151	CcSEcCtD
Epoprostenol—Fatigue—Methotrexate—breast cancer	2.64e-05	0.000151	CcSEcCtD
Epoprostenol—Infection—Doxorubicin—breast cancer	2.63e-05	0.00015	CcSEcCtD
Epoprostenol—Pain—Methotrexate—breast cancer	2.62e-05	0.000149	CcSEcCtD
Epoprostenol—Vomiting—Capecitabine—breast cancer	2.61e-05	0.000149	CcSEcCtD
Epoprostenol—Musculoskeletal discomfort—Epirubicin—breast cancer	2.61e-05	0.000149	CcSEcCtD
Epoprostenol—Shock—Doxorubicin—breast cancer	2.61e-05	0.000149	CcSEcCtD
Epoprostenol—Nervous system disorder—Doxorubicin—breast cancer	2.6e-05	0.000148	CcSEcCtD
Epoprostenol—Thrombocytopenia—Doxorubicin—breast cancer	2.6e-05	0.000148	CcSEcCtD
Epoprostenol—Rash—Capecitabine—breast cancer	2.59e-05	0.000148	CcSEcCtD
Epoprostenol—Insomnia—Epirubicin—breast cancer	2.59e-05	0.000148	CcSEcCtD
Epoprostenol—Dermatitis—Capecitabine—breast cancer	2.59e-05	0.000148	CcSEcCtD
Epoprostenol—Tachycardia—Doxorubicin—breast cancer	2.59e-05	0.000148	CcSEcCtD
Epoprostenol—Headache—Capecitabine—breast cancer	2.58e-05	0.000147	CcSEcCtD
Epoprostenol—Skin disorder—Doxorubicin—breast cancer	2.58e-05	0.000147	CcSEcCtD
Epoprostenol—Paraesthesia—Epirubicin—breast cancer	2.57e-05	0.000147	CcSEcCtD
Epoprostenol—Hyperhidrosis—Doxorubicin—breast cancer	2.56e-05	0.000146	CcSEcCtD
Epoprostenol—Dyspnoea—Epirubicin—breast cancer	2.55e-05	0.000146	CcSEcCtD
Epoprostenol—Somnolence—Epirubicin—breast cancer	2.55e-05	0.000145	CcSEcCtD
Epoprostenol—Anorexia—Doxorubicin—breast cancer	2.53e-05	0.000144	CcSEcCtD
Epoprostenol—Nausea—Docetaxel—breast cancer	2.52e-05	0.000144	CcSEcCtD
Epoprostenol—Dyspepsia—Epirubicin—breast cancer	2.52e-05	0.000144	CcSEcCtD
Epoprostenol—Gastrointestinal pain—Methotrexate—breast cancer	2.5e-05	0.000143	CcSEcCtD
Epoprostenol—Decreased appetite—Epirubicin—breast cancer	2.49e-05	0.000142	CcSEcCtD
Epoprostenol—Hypotension—Doxorubicin—breast cancer	2.48e-05	0.000141	CcSEcCtD
Epoprostenol—Gastrointestinal disorder—Epirubicin—breast cancer	2.47e-05	0.000141	CcSEcCtD
Epoprostenol—Fatigue—Epirubicin—breast cancer	2.47e-05	0.000141	CcSEcCtD
Epoprostenol—Pain—Epirubicin—breast cancer	2.45e-05	0.00014	CcSEcCtD
Epoprostenol—Constipation—Epirubicin—breast cancer	2.45e-05	0.00014	CcSEcCtD
Epoprostenol—Nausea—Capecitabine—breast cancer	2.44e-05	0.000139	CcSEcCtD
Epoprostenol—Urticaria—Methotrexate—breast cancer	2.43e-05	0.000139	CcSEcCtD
Epoprostenol—Body temperature increased—Methotrexate—breast cancer	2.42e-05	0.000138	CcSEcCtD
Epoprostenol—Abdominal pain—Methotrexate—breast cancer	2.42e-05	0.000138	CcSEcCtD
Epoprostenol—Musculoskeletal discomfort—Doxorubicin—breast cancer	2.42e-05	0.000138	CcSEcCtD
Epoprostenol—Insomnia—Doxorubicin—breast cancer	2.4e-05	0.000137	CcSEcCtD
Epoprostenol—Paraesthesia—Doxorubicin—breast cancer	2.38e-05	0.000136	CcSEcCtD
Epoprostenol—Dyspnoea—Doxorubicin—breast cancer	2.36e-05	0.000135	CcSEcCtD
Epoprostenol—Somnolence—Doxorubicin—breast cancer	2.36e-05	0.000135	CcSEcCtD
Epoprostenol—Gastrointestinal pain—Epirubicin—breast cancer	2.34e-05	0.000134	CcSEcCtD
Epoprostenol—Dyspepsia—Doxorubicin—breast cancer	2.33e-05	0.000133	CcSEcCtD
Epoprostenol—Decreased appetite—Doxorubicin—breast cancer	2.3e-05	0.000132	CcSEcCtD
Epoprostenol—Gastrointestinal disorder—Doxorubicin—breast cancer	2.29e-05	0.000131	CcSEcCtD
Epoprostenol—Fatigue—Doxorubicin—breast cancer	2.29e-05	0.00013	CcSEcCtD
Epoprostenol—Urticaria—Epirubicin—breast cancer	2.28e-05	0.00013	CcSEcCtD
Epoprostenol—Constipation—Doxorubicin—breast cancer	2.27e-05	0.000129	CcSEcCtD
Epoprostenol—Pain—Doxorubicin—breast cancer	2.27e-05	0.000129	CcSEcCtD
Epoprostenol—Body temperature increased—Epirubicin—breast cancer	2.26e-05	0.000129	CcSEcCtD
Epoprostenol—Abdominal pain—Epirubicin—breast cancer	2.26e-05	0.000129	CcSEcCtD
Epoprostenol—Hypersensitivity—Methotrexate—breast cancer	2.26e-05	0.000129	CcSEcCtD
Epoprostenol—Asthenia—Methotrexate—breast cancer	2.2e-05	0.000125	CcSEcCtD
Epoprostenol—Gastrointestinal pain—Doxorubicin—breast cancer	2.17e-05	0.000124	CcSEcCtD
Epoprostenol—Pruritus—Methotrexate—breast cancer	2.17e-05	0.000124	CcSEcCtD
Epoprostenol—Hypersensitivity—Epirubicin—breast cancer	2.11e-05	0.00012	CcSEcCtD
Epoprostenol—Urticaria—Doxorubicin—breast cancer	2.11e-05	0.00012	CcSEcCtD
Epoprostenol—Abdominal pain—Doxorubicin—breast cancer	2.1e-05	0.00012	CcSEcCtD
Epoprostenol—Body temperature increased—Doxorubicin—breast cancer	2.1e-05	0.00012	CcSEcCtD
Epoprostenol—Diarrhoea—Methotrexate—breast cancer	2.09e-05	0.00012	CcSEcCtD
Epoprostenol—Asthenia—Epirubicin—breast cancer	2.06e-05	0.000117	CcSEcCtD
Epoprostenol—Pruritus—Epirubicin—breast cancer	2.03e-05	0.000116	CcSEcCtD
Epoprostenol—Dizziness—Methotrexate—breast cancer	2.02e-05	0.000116	CcSEcCtD
Epoprostenol—Diarrhoea—Epirubicin—breast cancer	1.96e-05	0.000112	CcSEcCtD
Epoprostenol—Hypersensitivity—Doxorubicin—breast cancer	1.95e-05	0.000111	CcSEcCtD
Epoprostenol—Vomiting—Methotrexate—breast cancer	1.95e-05	0.000111	CcSEcCtD
Epoprostenol—Rash—Methotrexate—breast cancer	1.93e-05	0.00011	CcSEcCtD
Epoprostenol—Dermatitis—Methotrexate—breast cancer	1.93e-05	0.00011	CcSEcCtD
Epoprostenol—Headache—Methotrexate—breast cancer	1.92e-05	0.000109	CcSEcCtD
Epoprostenol—Asthenia—Doxorubicin—breast cancer	1.9e-05	0.000109	CcSEcCtD
Epoprostenol—Dizziness—Epirubicin—breast cancer	1.89e-05	0.000108	CcSEcCtD
Epoprostenol—Pruritus—Doxorubicin—breast cancer	1.88e-05	0.000107	CcSEcCtD
Epoprostenol—Vomiting—Epirubicin—breast cancer	1.82e-05	0.000104	CcSEcCtD
Epoprostenol—Nausea—Methotrexate—breast cancer	1.82e-05	0.000104	CcSEcCtD
Epoprostenol—Diarrhoea—Doxorubicin—breast cancer	1.81e-05	0.000104	CcSEcCtD
Epoprostenol—Rash—Epirubicin—breast cancer	1.81e-05	0.000103	CcSEcCtD
Epoprostenol—Dermatitis—Epirubicin—breast cancer	1.8e-05	0.000103	CcSEcCtD
Epoprostenol—Headache—Epirubicin—breast cancer	1.79e-05	0.000102	CcSEcCtD
Epoprostenol—Dizziness—Doxorubicin—breast cancer	1.75e-05	0.0001	CcSEcCtD
Epoprostenol—Nausea—Epirubicin—breast cancer	1.7e-05	9.71e-05	CcSEcCtD
Epoprostenol—Vomiting—Doxorubicin—breast cancer	1.69e-05	9.62e-05	CcSEcCtD
Epoprostenol—Rash—Doxorubicin—breast cancer	1.67e-05	9.54e-05	CcSEcCtD
Epoprostenol—Dermatitis—Doxorubicin—breast cancer	1.67e-05	9.53e-05	CcSEcCtD
Epoprostenol—Headache—Doxorubicin—breast cancer	1.66e-05	9.48e-05	CcSEcCtD
Epoprostenol—Nausea—Doxorubicin—breast cancer	1.57e-05	8.99e-05	CcSEcCtD
Epoprostenol—CYP2C9—Metabolism—ESRRA—breast cancer	8.55e-06	7.59e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—ANGPTL4—breast cancer	8.55e-06	7.59e-05	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—EGFR—breast cancer	8.54e-06	7.58e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—FN1—breast cancer	8.5e-06	7.55e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—FN1—breast cancer	8.5e-06	7.55e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—MAPK3—breast cancer	8.47e-06	7.51e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—NFKBIA—breast cancer	8.4e-06	7.46e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—NFKBIA—breast cancer	8.4e-06	7.46e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—NOTCH1—breast cancer	8.32e-06	7.38e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—NOTCH1—breast cancer	8.32e-06	7.38e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—BRAF—breast cancer	8.31e-06	7.38e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—PIK3CG—breast cancer	8.14e-06	7.22e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—APC—breast cancer	8.14e-06	7.22e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—PIK3CG—breast cancer	8.14e-06	7.22e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—KIT—breast cancer	8.14e-06	7.22e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—KIT—breast cancer	8.14e-06	7.22e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—APC—breast cancer	8.14e-06	7.22e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—CYP1B1—breast cancer	8.13e-06	7.21e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—HADHB—breast cancer	8.1e-06	7.19e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—GPI—breast cancer	8.1e-06	7.19e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—IGF1—breast cancer	8.1e-06	7.18e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—AKT2—breast cancer	8.09e-06	7.18e-05	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—KRAS—breast cancer	8.07e-06	7.16e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—EGFR—breast cancer	8.06e-06	7.15e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—EGF—breast cancer	8.04e-06	7.14e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—EGF—breast cancer	8.04e-06	7.14e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—MAPK3—breast cancer	7.79e-06	6.92e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—MAPK3—breast cancer	7.79e-06	6.92e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—PIK3CD—breast cancer	7.77e-06	6.9e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—NCOA1—breast cancer	7.75e-06	6.88e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—ALDH1A1—breast cancer	7.73e-06	6.86e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—ALDH7A1—breast cancer	7.73e-06	6.86e-05	CbGpPWpGaD
Epoprostenol—P2RY12—GPCR downstream signaling—PIK3CA—breast cancer	7.7e-06	6.83e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—SERPINE1—breast cancer	7.69e-06	6.82e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—BRAF—breast cancer	7.65e-06	6.79e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—BRAF—breast cancer	7.65e-06	6.79e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—CYP19A1—breast cancer	7.64e-06	6.78e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—KRAS—breast cancer	7.61e-06	6.75e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—IGF1—breast cancer	7.45e-06	6.61e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—IGF1—breast cancer	7.45e-06	6.61e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—AKT2—breast cancer	7.44e-06	6.61e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—AKT2—breast cancer	7.44e-06	6.61e-05	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—PIK3CA—breast cancer	7.42e-06	6.58e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—EGFR—breast cancer	7.41e-06	6.58e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—EGFR—breast cancer	7.41e-06	6.58e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—UMPS—breast cancer	7.41e-06	6.58e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—PHGDH—breast cancer	7.41e-06	6.58e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—FHL2—breast cancer	7.41e-06	6.58e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—ADSL—breast cancer	7.41e-06	6.58e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—NME1—breast cancer	7.41e-06	6.58e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—NOS3—breast cancer	7.34e-06	6.51e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—HPSE—breast cancer	7.27e-06	6.45e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—BRIP1—breast cancer	7.27e-06	6.45e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—LDHB—breast cancer	7.27e-06	6.45e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—PIK3CD—breast cancer	7.15e-06	6.35e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—PIK3CD—breast cancer	7.15e-06	6.35e-05	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR downstream signaling—PIK3CA—breast cancer	7.08e-06	6.29e-05	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR downstream signaling—PIK3CA—breast cancer	7.08e-06	6.29e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—SERPINE1—breast cancer	7.07e-06	6.28e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—SERPINE1—breast cancer	7.07e-06	6.28e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—KRAS—breast cancer	7e-06	6.22e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—KRAS—breast cancer	7e-06	6.22e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—PIK3CA—breast cancer	6.99e-06	6.2e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—MDM2—breast cancer	6.96e-06	6.18e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—RAF1—breast cancer	6.94e-06	6.16e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—RELA—breast cancer	6.91e-06	6.13e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—ABCC1—breast cancer	6.89e-06	6.11e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—HMMR—breast cancer	6.89e-06	6.11e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—GSTA3—breast cancer	6.89e-06	6.11e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—ERBB2—breast cancer	6.86e-06	6.09e-05	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—HRAS—breast cancer	6.86e-06	6.09e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—MTOR—breast cancer	6.77e-06	6.01e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—PIK3CB—breast cancer	6.77e-06	6.01e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—NOS3—breast cancer	6.75e-06	5.99e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—NOS3—breast cancer	6.75e-06	5.99e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—PPARGC1B—breast cancer	6.67e-06	5.92e-05	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—IL6—breast cancer	6.57e-06	5.83e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—CXCL8—breast cancer	6.51e-06	5.78e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—PLA2G4A—breast cancer	6.5e-06	5.77e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—NCOR1—breast cancer	6.5e-06	5.77e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—HRAS—breast cancer	6.47e-06	5.74e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—PIK3CA—breast cancer	6.43e-06	5.71e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—PIK3CA—breast cancer	6.43e-06	5.71e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—MDM2—breast cancer	6.41e-06	5.69e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—MDM2—breast cancer	6.41e-06	5.69e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—RAF1—breast cancer	6.39e-06	5.67e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—RAF1—breast cancer	6.39e-06	5.67e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—CDKN1B—breast cancer	6.36e-06	5.64e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—RELA—breast cancer	6.36e-06	5.64e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—RELA—breast cancer	6.36e-06	5.64e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—ERBB2—breast cancer	6.32e-06	5.61e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—ERBB2—breast cancer	6.32e-06	5.61e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—CA9—breast cancer	6.3e-06	5.59e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—GSTA4—breast cancer	6.3e-06	5.59e-05	CbGpPWpGaD
Epoprostenol—P2RY12—GPCR downstream signaling—AKT1—breast cancer	6.29e-06	5.58e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—PIK3CB—breast cancer	6.23e-06	5.53e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—MTOR—breast cancer	6.23e-06	5.53e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—MTOR—breast cancer	6.23e-06	5.53e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—PIK3CB—breast cancer	6.23e-06	5.53e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—CASP3—breast cancer	6.23e-06	5.53e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—IL2—breast cancer	6.22e-06	5.52e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—breast cancer	6.22e-06	5.52e-05	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—PIK3CA—breast cancer	6.21e-06	5.51e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—IL6—breast cancer	6.19e-06	5.49e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A1—breast cancer	6.16e-06	5.47e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—GSTA2—breast cancer	6.14e-06	5.45e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—GPX2—breast cancer	6.14e-06	5.45e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—GPX4—breast cancer	6.07e-06	5.38e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—SULT1A1—breast cancer	6.07e-06	5.38e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—CCND1—breast cancer	6.07e-06	5.38e-05	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—AKT1—breast cancer	6.06e-06	5.38e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—JUN—breast cancer	6.05e-06	5.37e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—CTNNB1—breast cancer	6.01e-06	5.33e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—CXCL8—breast cancer	5.99e-06	5.32e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—CXCL8—breast cancer	5.99e-06	5.32e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—HRAS—breast cancer	5.95e-06	5.28e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—HRAS—breast cancer	5.95e-06	5.28e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—IDH1—breast cancer	5.92e-06	5.26e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—GSTA1—breast cancer	5.92e-06	5.26e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—MMP9—breast cancer	5.89e-06	5.23e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—CDKN1A—breast cancer	5.87e-06	5.21e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—NAT2—breast cancer	5.86e-06	5.2e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—PTEN—breast cancer	5.85e-06	5.2e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—CDKN1B—breast cancer	5.85e-06	5.19e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—CDKN1B—breast cancer	5.85e-06	5.19e-05	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR downstream signaling—AKT1—breast cancer	5.79e-06	5.14e-05	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR downstream signaling—AKT1—breast cancer	5.79e-06	5.14e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—CASP3—breast cancer	5.73e-06	5.09e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—CASP3—breast cancer	5.73e-06	5.09e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—MAPK8—breast cancer	5.73e-06	5.08e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—IL2—breast cancer	5.73e-06	5.08e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—IL2—breast cancer	5.73e-06	5.08e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—AKT1—breast cancer	5.71e-06	5.07e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—IL6—breast cancer	5.7e-06	5.06e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—IL6—breast cancer	5.7e-06	5.06e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—CCND1—breast cancer	5.58e-06	4.95e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—CCND1—breast cancer	5.58e-06	4.95e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—JUN—breast cancer	5.57e-06	4.94e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—JUN—breast cancer	5.57e-06	4.94e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—CTNNB1—breast cancer	5.53e-06	4.91e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—CTNNB1—breast cancer	5.53e-06	4.91e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—SRC—breast cancer	5.43e-06	4.82e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—MMP9—breast cancer	5.42e-06	4.81e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—MMP9—breast cancer	5.42e-06	4.81e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—CDKN1A—breast cancer	5.4e-06	4.79e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—CDKN1A—breast cancer	5.4e-06	4.79e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—PTEN—breast cancer	5.39e-06	4.78e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—PTEN—breast cancer	5.39e-06	4.78e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—CAV1—breast cancer	5.3e-06	4.7e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—VEGFA—breast cancer	5.29e-06	4.69e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—MAPK8—breast cancer	5.27e-06	4.68e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—MAPK8—breast cancer	5.27e-06	4.68e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—AKT1—breast cancer	5.26e-06	4.66e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—AKT1—breast cancer	5.26e-06	4.66e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—STAT3—breast cancer	5.24e-06	4.65e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—MED12—breast cancer	5.14e-06	4.56e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—DPYD—breast cancer	5.14e-06	4.56e-05	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—AKT1—breast cancer	5.07e-06	4.5e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—ALDOA—breast cancer	5.06e-06	4.49e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—MAPK3—breast cancer	5e-06	4.44e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—SRC—breast cancer	5e-06	4.43e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—SRC—breast cancer	5e-06	4.43e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—NCOA3—breast cancer	4.91e-06	4.36e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—SLC2A2—breast cancer	4.87e-06	4.33e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—VEGFA—breast cancer	4.87e-06	4.32e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—VEGFA—breast cancer	4.87e-06	4.32e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—MYC—breast cancer	4.86e-06	4.32e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—TGFB1—breast cancer	4.85e-06	4.31e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—breast cancer	4.82e-06	4.28e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—STAT3—breast cancer	4.82e-06	4.28e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—STAT3—breast cancer	4.82e-06	4.28e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—CPT1A—breast cancer	4.78e-06	4.24e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—MTR—breast cancer	4.78e-06	4.24e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—ABCG2—breast cancer	4.78e-06	4.24e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—EGFR—breast cancer	4.76e-06	4.22e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—HPGDS—breast cancer	4.68e-06	4.16e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—HBA1—breast cancer	4.65e-06	4.13e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—MAPK3—breast cancer	4.6e-06	4.09e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—MAPK3—breast cancer	4.6e-06	4.09e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—GSTT1—breast cancer	4.54e-06	4.03e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—ACHE—breast cancer	4.54e-06	4.03e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—KRAS—breast cancer	4.5e-06	3.99e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—MYC—breast cancer	4.48e-06	3.97e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—MYC—breast cancer	4.48e-06	3.97e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—TGFB1—breast cancer	4.47e-06	3.96e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—TGFB1—breast cancer	4.47e-06	3.96e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—EGFR—breast cancer	4.38e-06	3.89e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—EGFR—breast cancer	4.38e-06	3.89e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—CYP17A1—breast cancer	4.3e-06	3.82e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—PTGS1—breast cancer	4.26e-06	3.78e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—ENO1—breast cancer	4.26e-06	3.78e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—breast cancer	4.24e-06	3.76e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—ALB—breast cancer	4.19e-06	3.72e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—CYP2D6—breast cancer	4.17e-06	3.7e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—KRAS—breast cancer	4.14e-06	3.67e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—KRAS—breast cancer	4.14e-06	3.67e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—PIK3CA—breast cancer	4.13e-06	3.67e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—NCOA2—breast cancer	4.1e-06	3.64e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—TP53—breast cancer	4e-06	3.55e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—FASN—breast cancer	3.97e-06	3.53e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—BCHE—breast cancer	3.96e-06	3.51e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—SLC5A5—breast cancer	3.91e-06	3.47e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—HRAS—breast cancer	3.82e-06	3.39e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—PIK3CA—breast cancer	3.8e-06	3.37e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—PIK3CA—breast cancer	3.8e-06	3.37e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—SLC2A1—breast cancer	3.77e-06	3.35e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—NQO1—breast cancer	3.77e-06	3.35e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—breast cancer	3.7e-06	3.28e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—CYP3A4—breast cancer	3.68e-06	3.27e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—TP53—breast cancer	3.68e-06	3.26e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—TP53—breast cancer	3.68e-06	3.26e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—breast cancer	3.66e-06	3.25e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—IL6—breast cancer	3.66e-06	3.25e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—CYP1B1—breast cancer	3.62e-06	3.21e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—HSP90AA1—breast cancer	3.55e-06	3.15e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—HRAS—breast cancer	3.52e-06	3.12e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—HRAS—breast cancer	3.52e-06	3.12e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—NCOA1—breast cancer	3.45e-06	3.06e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—STK11—breast cancer	3.4e-06	3.02e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—CYP19A1—breast cancer	3.4e-06	3.02e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—AKT1—breast cancer	3.37e-06	2.99e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—IL6—breast cancer	3.37e-06	2.99e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—IL6—breast cancer	3.37e-06	2.99e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—breast cancer	3.19e-06	2.83e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—COMT—breast cancer	3.16e-06	2.81e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—GSTP1—breast cancer	3.15e-06	2.79e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—HMOX1—breast cancer	3.1e-06	2.76e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—AKT1—breast cancer	3.1e-06	2.76e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—AKT1—breast cancer	3.1e-06	2.76e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—ITPR1—breast cancer	3.1e-06	2.75e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—ABCB1—breast cancer	2.98e-06	2.65e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—TYMS—breast cancer	2.93e-06	2.6e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—NCOR1—breast cancer	2.89e-06	2.57e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—PLA2G4A—breast cancer	2.89e-06	2.57e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—GSTM1—breast cancer	2.89e-06	2.57e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—GPX1—breast cancer	2.77e-06	2.46e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—CYP1A1—breast cancer	2.74e-06	2.43e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—ERCC2—breast cancer	2.72e-06	2.41e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—MTHFR—breast cancer	2.56e-06	2.27e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—CAV1—breast cancer	2.36e-06	2.09e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—breast cancer	2.25e-06	2e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—PIK3CG—breast cancer	2.15e-06	1.91e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—PIK3CD—breast cancer	1.89e-06	1.68e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—ALB—breast cancer	1.86e-06	1.65e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—NOS3—breast cancer	1.78e-06	1.58e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—PIK3CB—breast cancer	1.65e-06	1.46e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—PTGS2—breast cancer	1.63e-06	1.45e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—PTEN—breast cancer	1.42e-06	1.26e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—PIK3CA—breast cancer	1e-06	8.91e-06	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—AKT1—breast cancer	8.2e-07	7.28e-06	CbGpPWpGaD
